✦ LIBER ✦

Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer

✍ Scribed by Angelo Dinota; Domenico Bilancia; Rosangela Romano; Luigi Manzione

Publisher: Springer US
Year: 2005
Tongue: English
Weight: 71 KB
Volume: 89
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-004-1000-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epirubicin or epirubicin and cisplatin a

Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study

✍ Dorte Nielsen; Per Dombernowsky; Susanne Kornum Larsen; Ole Paaske Hansen; Torbe 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 115 KB

Randomized phase 2 study of irinotecan p

Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer

✍ Ji-Youn Han; Dae Ho Lee; Jung Eun Song; Sung Young Lee; Hyae Young Kim; Heung Ta 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

Phase II study of vinorelbine (alternati

Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer

✍ Mario Campone; Maria Blasinska-Morawiec; Anna Tekiela; Piotr Koralewski; Jean-Ch 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 297 KB

Dose-finding study of weekly docetaxel,

Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer

✍ S. H. Waters; A. Gillibrand; H. Berry; S. Kumar; G. Velikova; D. J. Dodwell; Tim 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 223 KB

A phase II trial of mitomycin C and 5-fl

A phase II trial of mitomycin C and 5-fluorouracil as second-line therapy in advanced breast cancer

✍ Mary E R O'Brien; E J Bayliss; Moira E Stewart; John F Smyth; Alan Rodger; R C F 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 195 KB

Final results of a phase II study ofnab-

Final results of a phase II study ofnab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

✍ Christopher Lobo; Gilberto Lopes; Odalys Baez; Aurelio Castrellon; Annapoorna Fe 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 268 KB